HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taku, K. Articles by Watanabe, S. Search for Related Content PubMed PubMed Citation Articles by Taku, K. Articles by Watanabe, S. Agricola Articles by Taku, K. Articles by Watanabe, S.

Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials ^1,2,3

¹ From the Information Center (KT, KU, YS, YT, and KE) and the Nutritional Education Program (SW), National Institute of Health and Nutrition, Tokyo, Japan

Background: Clinical trials have reported the cholesterol-lowering effects of soy protein intake, but the components responsible are not known.

Objective: This meta-analysis was primarily conducted to evaluate the precise effects of soy isoflavones on lipid profiles. The effects of soy protein that contains enriched and depleted isoflavones were also examined.

Design: PUBMED was searched for English-language reports of randomized controlled trials published from 1990 to 2006 that described the effects of soy protein intake in humans. Eleven studies were selected for the meta-analysis.

Results: Soy isoflavones significantly decreased serum total cholesterol by 0.10 mmol/L (3.9 mg/dL or 1.77%; P = 0.02) and LDL cholesterol by 0.13 mmol/L (5.0 mg/dL or 3.58%; P < 0.0001); no significant changes in HDL cholesterol and triacylglycerol were found. Isoflavone-depleted soy protein significantly decreased LDL cholesterol by 0.10 mmol/L (3.9 mg/dL or 2.77%; P = 0.03). Soy protein that contained enriched isoflavones significantly decreased LDL cholesterol by 0.18 mmol/L (7.0 mg/dL or 4.98%; P < 0.0001) and significantly increased HDL cholesterol by 0.04 mmol/L (1.6 mg/dL or 3.00%; P = 0.05). The reductions in LDL cholesterol were larger in the hypercholesterolemic subcategory than in the normocholesterolemic subcategory, but no significant linear correlations were observed between reductions and the starting values. No significant linear correlations were found between reductions in LDL cholesterol and soy protein ingestion or isoflavone intakes.

Conclusions: Soy isoflavones significantly reduced serum total and LDL cholesterol but did not change HDL cholesterol and triacylglycerol. Soy protein that contained enriched or depleted isoflavones also significantly improved lipid profiles. Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.

Key Words: Soy isoflavones • soy protein • lipid • total cholesterol • LDL cholesterol • HDL cholesterol • triacylglycerol • meta-analysis

This article has been cited by other articles:

				M. V. Potenza and J. I. Mechanick The Metabolic Syndrome: Definition, Global Impact, and Pathophysiology Nutr Clin Pract, October 1, 2009; 24(5): 560 - 577. [Abstract] [Full Text] [PDF]

				E. A. Pipe, C. P. Gobert, S. E. Capes, G. A. Darlington, J. W. Lampe, and A. M. Duncan Soy Protein Reduces Serum LDL Cholesterol and the LDL Cholesterol:HDL Cholesterol and Apolipoprotein B:Apolipoprotein A-I Ratios in Adults with Type 2 Diabetes J. Nutr., September 1, 2009; 139(9): 1700 - 1706. [Abstract] [Full Text] [PDF]

				M. Messina, S. Watanabe, and K. D. R. Setchell Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment J. Nutr., April 1, 2009; 139(4): 796S - 802S. [Abstract] [Full Text] [PDF]

				M. J. Morrison, E. R. Cober, M. F. Saleem, N. B. McLaughlin, J. Fregeau-Reid, B. L. Ma, W. Yan, and L. Woodrow Changes in Isoflavone Concentration with 58 Years of Genetic Improvement of Short-Season Soybean Cultivars in Canada Crop Sci., November 24, 2008; 48(6): 2201 - 2208. [Abstract] [Full Text] [PDF]

				A. Orgaard and L. Jensen The Effects of Soy Isoflavones on Obesity Experimental Biology and Medicine, September 1, 2008; 233(9): 1066 - 1080. [Abstract] [Full Text] [PDF]

				A. A Thorp, P. R. Howe, T. A Mori, A. M Coates, J. D Buckley, J. Hodgson, J. Mansour, and B. J Meyer Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 298 - 304. [Abstract] [Full Text] [PDF]

				J. M Geleijnse and P. C. Hollman Flavonoids and cardiovascular health: which compounds, what mechanisms? Am. J. Clinical Nutrition, July 1, 2008; 88(1): 12 - 13. [Full Text] [PDF]

				L. Hooper, P. A Kroon, E. B Rimm, J. S Cohn, I. Harvey, K. A Le Cornu, J. J Ryder, W. L Hall, and A. Cassidy Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials Am. J. Clinical Nutrition, July 1, 2008; 88(1): 38 - 50. [Abstract] [Full Text] [PDF]

				I. Rudkowska Functional foods for cardiovascular disease in women Menopause Int, June 1, 2008; 14(2): 63 - 69. [Abstract] [Full Text] [PDF]

				S. Vosough-Ghanbari, R. Rahimi, S. Kharabaf, S. Zeinali, A. Mohammadirad, S. Amini, N. Yasa, A. Salehnia, T. Toliat, S. Nikfar, et al. Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial Evid. Based Complement. Altern. Med., February 27, 2008; (2008) nen018v1. [Abstract] [Full Text] [PDF]

				Y.-H. Chan, K.-K. Lau, K.-H. Yiu, S.-W. Li, H.-T. Chan, S. Tam, X.-O. Shu, C.-P. Lau, and H.-F. Tse Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden Am. J. Clinical Nutrition, October 1, 2007; 86(4): 938 - 945. [Abstract] [Full Text] [PDF]